In TCGA database, patients with high expression of GPR17 survived longer than the patients with a low level of GPR17 (Fig. 1F), and the Gliovis database (http://gliovis.bioinfo.cnio.es/) revealed that the expression level of GPR17 gradually reduced during glioma exacerbation from Grade II to Grade IV (Fig. 1G). Here, GPR17 is linked to central nervous system cancer.